Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ATR-04
ATR04-484 · 1 trial · 1 indication
Treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| ATR04-484 | EXPERIMENTAL | Topically applied ATR04-484 |
| Vehicle | PLACEBO_COMPARATOR | Topically applied vehicle |
| Name | Type | Description |
|---|---|---|
| ATR04-484 | DRUG | ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use |
| Vehicle | DRUG | Topically applied vehicle. |
Inclusion Criteria: * Adults ≥18 years of age * Currently treated with an FDA-approved EGFRi, KRASi, or MEKi (or other medications in the pathway, if approved by the Medical Monitor) for the treatment of cancer with or without concurrent chemotherapy, or for neurofibromatosis, and expected to conti...
ATR04-484 is an investigational small molecule being developed for the treatment of EGFR inhibitor-associated rash, a dermatologic condition that can occur in patients receiving EGFR inhibitor therapy. It is currently in Phase 1 clinical development.
ATR04-484 targets EGFR, the epidermal growth factor receptor. By targeting this protein, the drug is designed to address EGFR inhibitor-associated rash, a dermatologic toxicity linked to EGFR pathway activity.
ATR04-484 is being developed by Azitra Inc, a biopharmaceutical company. Azitra's stock is traded under the ticker symbol AZTR on the stock market.
ATR04-484 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug has received Fast Track designation from the FDA.
ATR04-484 is being evaluated in a Phase 1 clinical trial with the identifier NCT06830863. This randomized, double-blind, placebo-controlled study is recruiting 32 participants in the United States to evaluate the drug for EGFR inhibitor-associated rash.
No, ATR04-484 is a distinct investigational drug. It is not known to be the same as any other approved or investigational medication. It is being studied specifically for its potential to treat EGFR inhibitor-associated rash.